Antibody molecules to C5AR1 and uses thereof

Patent metadata

Field	Value
Publication number	US-12187807-B2
Application number	US-202318452173-A
Country	US
Kind code	B2
Filing date	Aug 18, 2023
Priority date	Jan 13, 2020
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

First claim

The invention claimed is:

1. An antibody molecule capable of binding to complement component 5a receptor 1 (C5aR1), comprising a VH and a VL, wherein the VH comprises:
i. an HCDR1 comprising an amino acid sequence of SEQ ID NO: 602;
ii. an HCDR2 comprising an amino acid sequence of SEQ ID NO: 722; and
iii. an HCDR3 comprising an amino acid sequence of SEQ ID NO: 842; and wherein the VL comprises:
i. an LCDR1 comprising an amino acid sequence of SEQ ID NO: 662,
ii. an LCDR2 comprising an amino acid sequence of SEQ ID NO: 782, and
iii. an LCDR3 comprising an amino acid sequence of SEQ ID NO: 902.

2. The antibody of claim 1 , wherein the VH comprises SEQ ID NO: 482, and the VL comprises SEQ ID NO: 542.

3. A pharmaceutical composition comprising the antibody molecule of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.

4. A combination comprising the antibody molecule of claim 1 , and a second therapeutic agent.

Assignees

• Visterra Inc

Inventors

• Viswanathan Karthik
• Booth Brian
• Ramakrishnan Boopathy
• Wollacott Andrew
• Babcock Gregory
• Shriver Zachary

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K2317/31

  multispecific · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K2317/622

  Single chain antibody (scFv) · CPC title